nodes	percent_of_prediction	percent_of_DWPC	metapath
Cilostazol—CYP2D6—Fingolimod—multiple sclerosis	0.101	0.163	CbGbCtD
Cilostazol—CYP3A4—Fingolimod—multiple sclerosis	0.0644	0.104	CbGbCtD
Cilostazol—CYP3A7—Dexamethasone—multiple sclerosis	0.0537	0.0865	CbGbCtD
Cilostazol—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.0537	0.0865	CbGbCtD
Cilostazol—CYP2C19—Prednisone—multiple sclerosis	0.052	0.0839	CbGbCtD
Cilostazol—CYP3A4—Methylprednisolone—multiple sclerosis	0.0415	0.0669	CbGbCtD
Cilostazol—CYP3A5—Dexamethasone—multiple sclerosis	0.0403	0.0649	CbGbCtD
Cilostazol—CYP2C19—Dexamethasone—multiple sclerosis	0.0325	0.0524	CbGbCtD
Cilostazol—CYP3A4—Triamcinolone—multiple sclerosis	0.0315	0.0507	CbGbCtD
Cilostazol—CYP3A4—Mitoxantrone—multiple sclerosis	0.0303	0.0488	CbGbCtD
Cilostazol—CYP3A4—Betamethasone—multiple sclerosis	0.027	0.0435	CbGbCtD
Cilostazol—CYP3A4—Prednisolone—multiple sclerosis	0.0266	0.0429	CbGbCtD
Cilostazol—CYP3A4—Prednisone—multiple sclerosis	0.0252	0.0405	CbGbCtD
Cilostazol—CYP2D6—Dexamethasone—multiple sclerosis	0.0247	0.0398	CbGbCtD
Cilostazol—CYP3A4—Dexamethasone—multiple sclerosis	0.0157	0.0253	CbGbCtD
Cilostazol—CYP3A5—Irinotecan Pathway—BCHE—multiple sclerosis	0.000345	0.022	CbGpPWpGaD
Cilostazol—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000342	0.0218	CbGpPWpGaD
Cilostazol—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000342	0.0218	CbGpPWpGaD
Cilostazol—CYP3A7—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000338	0.0215	CbGpPWpGaD
Cilostazol—CYP3A7—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000338	0.0215	CbGpPWpGaD
Cilostazol—Tachycardia—Prednisolone—multiple sclerosis	0.000295	0.000812	CcSEcCtD
Cilostazol—Hypertension—Triamcinolone—multiple sclerosis	0.000294	0.000809	CcSEcCtD
Cilostazol—Hypertension—Methylprednisolone—multiple sclerosis	0.000294	0.000807	CcSEcCtD
Cilostazol—Urticaria—Mitoxantrone—multiple sclerosis	0.000293	0.000805	CcSEcCtD
Cilostazol—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000292	0.000801	CcSEcCtD
Cilostazol—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000292	0.000801	CcSEcCtD
Cilostazol—Myalgia—Triamcinolone—multiple sclerosis	0.00029	0.000798	CcSEcCtD
Cilostazol—Vomiting—Azathioprine—multiple sclerosis	0.00029	0.000797	CcSEcCtD
Cilostazol—Pneumonia—Methotrexate—multiple sclerosis	0.00029	0.000797	CcSEcCtD
Cilostazol—Arthralgia—Methylprednisolone—multiple sclerosis	0.00029	0.000796	CcSEcCtD
Cilostazol—Myalgia—Methylprednisolone—multiple sclerosis	0.00029	0.000796	CcSEcCtD
Cilostazol—Anxiety—Methylprednisolone—multiple sclerosis	0.000289	0.000793	CcSEcCtD
Cilostazol—Rash—Azathioprine—multiple sclerosis	0.000288	0.000791	CcSEcCtD
Cilostazol—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000288	0.000791	CcSEcCtD
Cilostazol—Dermatitis—Azathioprine—multiple sclerosis	0.000287	0.00079	CcSEcCtD
Cilostazol—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000287	0.000789	CcSEcCtD
Cilostazol—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000287	0.000789	CcSEcCtD
Cilostazol—Discomfort—Triamcinolone—multiple sclerosis	0.000287	0.000788	CcSEcCtD
Cilostazol—Discomfort—Methylprednisolone—multiple sclerosis	0.000286	0.000787	CcSEcCtD
Cilostazol—Headache—Azathioprine—multiple sclerosis	0.000286	0.000786	CcSEcCtD
Cilostazol—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000286	0.000785	CcSEcCtD
Cilostazol—Angiopathy—Prednisone—multiple sclerosis	0.000281	0.000772	CcSEcCtD
Cilostazol—Conjunctivitis—Methotrexate—multiple sclerosis	0.00028	0.00077	CcSEcCtD
Cilostazol—Malaise—Dexamethasone—multiple sclerosis	0.000279	0.000767	CcSEcCtD
Cilostazol—Malaise—Betamethasone—multiple sclerosis	0.000279	0.000767	CcSEcCtD
Cilostazol—Oedema—Triamcinolone—multiple sclerosis	0.000278	0.000765	CcSEcCtD
Cilostazol—Vertigo—Betamethasone—multiple sclerosis	0.000278	0.000764	CcSEcCtD
Cilostazol—Vertigo—Dexamethasone—multiple sclerosis	0.000278	0.000764	CcSEcCtD
Cilostazol—CYP3A7—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000278	0.0177	CbGpPWpGaD
Cilostazol—CYP3A7—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000278	0.0177	CbGpPWpGaD
Cilostazol—Syncope—Dexamethasone—multiple sclerosis	0.000277	0.000763	CcSEcCtD
Cilostazol—Syncope—Betamethasone—multiple sclerosis	0.000277	0.000763	CcSEcCtD
Cilostazol—Infection—Triamcinolone—multiple sclerosis	0.000276	0.00076	CcSEcCtD
Cilostazol—Infection—Methylprednisolone—multiple sclerosis	0.000276	0.000758	CcSEcCtD
Cilostazol—Haematuria—Methotrexate—multiple sclerosis	0.000275	0.000755	CcSEcCtD
Cilostazol—Shock—Triamcinolone—multiple sclerosis	0.000274	0.000752	CcSEcCtD
Cilostazol—Insomnia—Prednisolone—multiple sclerosis	0.000274	0.000752	CcSEcCtD
Cilostazol—Shock—Methylprednisolone—multiple sclerosis	0.000273	0.000751	CcSEcCtD
Cilostazol—Hepatobiliary disease—Methotrexate—multiple sclerosis	0.000273	0.000749	CcSEcCtD
Cilostazol—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000272	0.000748	CcSEcCtD
Cilostazol—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000272	0.000747	CcSEcCtD
Cilostazol—Loss of consciousness—Betamethasone—multiple sclerosis	0.000272	0.000747	CcSEcCtD
Cilostazol—Epistaxis—Methotrexate—multiple sclerosis	0.000272	0.000747	CcSEcCtD
Cilostazol—Paraesthesia—Prednisolone—multiple sclerosis	0.000272	0.000747	CcSEcCtD
Cilostazol—Tachycardia—Triamcinolone—multiple sclerosis	0.000272	0.000746	CcSEcCtD
Cilostazol—Nausea—Azathioprine—multiple sclerosis	0.000271	0.000745	CcSEcCtD
Cilostazol—Tachycardia—Methylprednisolone—multiple sclerosis	0.000271	0.000745	CcSEcCtD
Cilostazol—Skin disorder—Methylprednisolone—multiple sclerosis	0.00027	0.000741	CcSEcCtD
Cilostazol—Agranulocytosis—Methotrexate—multiple sclerosis	0.000269	0.000739	CcSEcCtD
Cilostazol—Hypertension—Dexamethasone—multiple sclerosis	0.000267	0.000734	CcSEcCtD
Cilostazol—Hypertension—Betamethasone—multiple sclerosis	0.000267	0.000734	CcSEcCtD
Cilostazol—Asthenia—Mitoxantrone—multiple sclerosis	0.000265	0.000727	CcSEcCtD
Cilostazol—Myalgia—Dexamethasone—multiple sclerosis	0.000263	0.000724	CcSEcCtD
Cilostazol—Myalgia—Betamethasone—multiple sclerosis	0.000263	0.000724	CcSEcCtD
Cilostazol—Anxiety—Dexamethasone—multiple sclerosis	0.000262	0.000721	CcSEcCtD
Cilostazol—Anxiety—Betamethasone—multiple sclerosis	0.000262	0.000721	CcSEcCtD
Cilostazol—Discomfort—Dexamethasone—multiple sclerosis	0.00026	0.000715	CcSEcCtD
Cilostazol—Discomfort—Betamethasone—multiple sclerosis	0.00026	0.000715	CcSEcCtD
Cilostazol—Haemoglobin—Methotrexate—multiple sclerosis	0.00026	0.000715	CcSEcCtD
Cilostazol—Hypotension—Methylprednisolone—multiple sclerosis	0.000259	0.000713	CcSEcCtD
Cilostazol—Pain—Prednisolone—multiple sclerosis	0.000259	0.000711	CcSEcCtD
Cilostazol—Haemorrhage—Methotrexate—multiple sclerosis	0.000259	0.000711	CcSEcCtD
Cilostazol—Pharyngitis—Methotrexate—multiple sclerosis	0.000257	0.000706	CcSEcCtD
Cilostazol—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000254	0.000697	CcSEcCtD
Cilostazol—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000253	0.000695	CcSEcCtD
Cilostazol—Oedema—Dexamethasone—multiple sclerosis	0.000253	0.000694	CcSEcCtD
Cilostazol—Oedema—Betamethasone—multiple sclerosis	0.000253	0.000694	CcSEcCtD
Cilostazol—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000252	0.000694	CcSEcCtD
Cilostazol—Insomnia—Triamcinolone—multiple sclerosis	0.000252	0.000692	CcSEcCtD
Cilostazol—Insomnia—Methylprednisolone—multiple sclerosis	0.000251	0.00069	CcSEcCtD
Cilostazol—Infection—Betamethasone—multiple sclerosis	0.000251	0.000689	CcSEcCtD
Cilostazol—Infection—Dexamethasone—multiple sclerosis	0.000251	0.000689	CcSEcCtD
Cilostazol—Ill-defined disorder—Prednisone—multiple sclerosis	0.00025	0.000687	CcSEcCtD
Cilostazol—Paraesthesia—Triamcinolone—multiple sclerosis	0.00025	0.000687	CcSEcCtD
Cilostazol—Feeling abnormal—Prednisolone—multiple sclerosis	0.000249	0.000685	CcSEcCtD
Cilostazol—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000249	0.000685	CcSEcCtD
Cilostazol—Anaemia—Prednisone—multiple sclerosis	0.000249	0.000684	CcSEcCtD
Cilostazol—Shock—Betamethasone—multiple sclerosis	0.000248	0.000683	CcSEcCtD
Cilostazol—Shock—Dexamethasone—multiple sclerosis	0.000248	0.000683	CcSEcCtD
Cilostazol—Dyspnoea—Triamcinolone—multiple sclerosis	0.000248	0.000682	CcSEcCtD
Cilostazol—Nervous system disorder—Betamethasone—multiple sclerosis	0.000248	0.000681	CcSEcCtD
Cilostazol—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000248	0.000681	CcSEcCtD
Cilostazol—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000248	0.0158	CbGpPWpGaD
Cilostazol—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000248	0.0158	CbGpPWpGaD
Cilostazol—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000247	0.000679	CcSEcCtD
Cilostazol—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000247	0.000679	CcSEcCtD
Cilostazol—Tachycardia—Dexamethasone—multiple sclerosis	0.000246	0.000677	CcSEcCtD
Cilostazol—Tachycardia—Betamethasone—multiple sclerosis	0.000246	0.000677	CcSEcCtD
Cilostazol—Dyspepsia—Triamcinolone—multiple sclerosis	0.000245	0.000673	CcSEcCtD
Cilostazol—Erythema multiforme—Methotrexate—multiple sclerosis	0.000245	0.000672	CcSEcCtD
Cilostazol—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000244	0.000672	CcSEcCtD
Cilostazol—CYP3A5—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000244	0.0156	CbGpPWpGaD
Cilostazol—CYP3A5—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000244	0.0156	CbGpPWpGaD
Cilostazol—Malaise—Prednisone—multiple sclerosis	0.000243	0.000668	CcSEcCtD
Cilostazol—Vertigo—Prednisone—multiple sclerosis	0.000242	0.000665	CcSEcCtD
Cilostazol—Syncope—Prednisone—multiple sclerosis	0.000242	0.000664	CcSEcCtD
Cilostazol—Tinnitus—Methotrexate—multiple sclerosis	0.000241	0.000663	CcSEcCtD
Cilostazol—Anorexia—Betamethasone—multiple sclerosis	0.000241	0.000661	CcSEcCtD
Cilostazol—Anorexia—Dexamethasone—multiple sclerosis	0.000241	0.000661	CcSEcCtD
Cilostazol—Urticaria—Prednisolone—multiple sclerosis	0.00024	0.000661	CcSEcCtD
Cilostazol—Cardiac disorder—Methotrexate—multiple sclerosis	0.00024	0.00066	CcSEcCtD
Cilostazol—Pain—Triamcinolone—multiple sclerosis	0.000238	0.000654	CcSEcCtD
Cilostazol—Loss of consciousness—Prednisone—multiple sclerosis	0.000237	0.000651	CcSEcCtD
Cilostazol—Hypotension—Betamethasone—multiple sclerosis	0.000236	0.000648	CcSEcCtD
Cilostazol—Hypotension—Dexamethasone—multiple sclerosis	0.000236	0.000648	CcSEcCtD
Cilostazol—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000235	0.015	CbGpPWpGaD
Cilostazol—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000235	0.015	CbGpPWpGaD
Cilostazol—Angiopathy—Methotrexate—multiple sclerosis	0.000235	0.000645	CcSEcCtD
Cilostazol—Vomiting—Mitoxantrone—multiple sclerosis	0.000235	0.000645	CcSEcCtD
Cilostazol—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000233	0.000641	CcSEcCtD
Cilostazol—Hypertension—Prednisone—multiple sclerosis	0.000233	0.000639	CcSEcCtD
Cilostazol—Rash—Mitoxantrone—multiple sclerosis	0.000233	0.000639	CcSEcCtD
Cilostazol—Dermatitis—Mitoxantrone—multiple sclerosis	0.000232	0.000639	CcSEcCtD
Cilostazol—Chills—Methotrexate—multiple sclerosis	0.000232	0.000638	CcSEcCtD
Cilostazol—Headache—Mitoxantrone—multiple sclerosis	0.000231	0.000635	CcSEcCtD
Cilostazol—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.00023	0.000632	CcSEcCtD
Cilostazol—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.00023	0.000632	CcSEcCtD
Cilostazol—Myalgia—Prednisone—multiple sclerosis	0.000229	0.00063	CcSEcCtD
Cilostazol—Arthralgia—Prednisone—multiple sclerosis	0.000229	0.00063	CcSEcCtD
Cilostazol—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000229	0.00063	CcSEcCtD
Cilostazol—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000229	0.000629	CcSEcCtD
Cilostazol—Anxiety—Prednisone—multiple sclerosis	0.000229	0.000628	CcSEcCtD
Cilostazol—Insomnia—Dexamethasone—multiple sclerosis	0.000228	0.000628	CcSEcCtD
Cilostazol—Insomnia—Betamethasone—multiple sclerosis	0.000228	0.000628	CcSEcCtD
Cilostazol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000228	0.000626	CcSEcCtD
Cilostazol—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000227	0.000624	CcSEcCtD
Cilostazol—Paraesthesia—Dexamethasone—multiple sclerosis	0.000227	0.000623	CcSEcCtD
Cilostazol—Paraesthesia—Betamethasone—multiple sclerosis	0.000227	0.000623	CcSEcCtD
Cilostazol—Discomfort—Prednisone—multiple sclerosis	0.000227	0.000623	CcSEcCtD
Cilostazol—Dyspepsia—Betamethasone—multiple sclerosis	0.000222	0.000611	CcSEcCtD
Cilostazol—Dyspepsia—Dexamethasone—multiple sclerosis	0.000222	0.000611	CcSEcCtD
Cilostazol—Urticaria—Triamcinolone—multiple sclerosis	0.000221	0.000608	CcSEcCtD
Cilostazol—Urticaria—Methylprednisolone—multiple sclerosis	0.000221	0.000606	CcSEcCtD
Cilostazol—Body temperature increased—Triamcinolone—multiple sclerosis	0.00022	0.000605	CcSEcCtD
Cilostazol—Oedema—Prednisone—multiple sclerosis	0.00022	0.000604	CcSEcCtD
Cilostazol—Abdominal pain—Methylprednisolone—multiple sclerosis	0.00022	0.000603	CcSEcCtD
Cilostazol—Decreased appetite—Dexamethasone—multiple sclerosis	0.00022	0.000603	CcSEcCtD
Cilostazol—Decreased appetite—Betamethasone—multiple sclerosis	0.00022	0.000603	CcSEcCtD
Cilostazol—Nausea—Mitoxantrone—multiple sclerosis	0.000219	0.000602	CcSEcCtD
Cilostazol—Infection—Prednisone—multiple sclerosis	0.000218	0.0006	CcSEcCtD
Cilostazol—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000218	0.000599	CcSEcCtD
Cilostazol—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000218	0.000599	CcSEcCtD
Cilostazol—Back pain—Methotrexate—multiple sclerosis	0.000218	0.000599	CcSEcCtD
Cilostazol—Shock—Prednisone—multiple sclerosis	0.000216	0.000595	CcSEcCtD
Cilostazol—Pain—Betamethasone—multiple sclerosis	0.000216	0.000593	CcSEcCtD
Cilostazol—Pain—Dexamethasone—multiple sclerosis	0.000216	0.000593	CcSEcCtD
Cilostazol—Nervous system disorder—Prednisone—multiple sclerosis	0.000216	0.000593	CcSEcCtD
Cilostazol—Tachycardia—Prednisone—multiple sclerosis	0.000215	0.00059	CcSEcCtD
Cilostazol—Skin disorder—Prednisone—multiple sclerosis	0.000214	0.000587	CcSEcCtD
Cilostazol—Anorexia—Prednisone—multiple sclerosis	0.00021	0.000576	CcSEcCtD
Cilostazol—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000209	0.000574	CcSEcCtD
Cilostazol—Anaemia—Methotrexate—multiple sclerosis	0.000208	0.000572	CcSEcCtD
Cilostazol—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000208	0.000572	CcSEcCtD
Cilostazol—Feeling abnormal—Betamethasone—multiple sclerosis	0.000208	0.000572	CcSEcCtD
Cilostazol—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000206	0.000567	CcSEcCtD
Cilostazol—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000206	0.000567	CcSEcCtD
Cilostazol—Malaise—Methotrexate—multiple sclerosis	0.000203	0.000558	CcSEcCtD
Cilostazol—Vertigo—Methotrexate—multiple sclerosis	0.000202	0.000556	CcSEcCtD
Cilostazol—Leukopenia—Methotrexate—multiple sclerosis	0.000202	0.000554	CcSEcCtD
Cilostazol—CYP3A5—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000201	0.0128	CbGpPWpGaD
Cilostazol—CYP3A5—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000201	0.0128	CbGpPWpGaD
Cilostazol—Urticaria—Dexamethasone—multiple sclerosis	0.000201	0.000551	CcSEcCtD
Cilostazol—Urticaria—Betamethasone—multiple sclerosis	0.000201	0.000551	CcSEcCtD
Cilostazol—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.0002	0.000551	CcSEcCtD
Cilostazol—Dizziness—Prednisolone—multiple sclerosis	0.0002	0.00055	CcSEcCtD
Cilostazol—Asthenia—Triamcinolone—multiple sclerosis	0.0002	0.000549	CcSEcCtD
Cilostazol—Abdominal pain—Betamethasone—multiple sclerosis	0.0002	0.000549	CcSEcCtD
Cilostazol—Body temperature increased—Betamethasone—multiple sclerosis	0.0002	0.000549	CcSEcCtD
Cilostazol—Body temperature increased—Dexamethasone—multiple sclerosis	0.0002	0.000549	CcSEcCtD
Cilostazol—Abdominal pain—Dexamethasone—multiple sclerosis	0.0002	0.000549	CcSEcCtD
Cilostazol—Asthenia—Methylprednisolone—multiple sclerosis	0.000199	0.000548	CcSEcCtD
Cilostazol—Insomnia—Prednisone—multiple sclerosis	0.000199	0.000547	CcSEcCtD
Cilostazol—Paraesthesia—Prednisone—multiple sclerosis	0.000197	0.000543	CcSEcCtD
Cilostazol—Pruritus—Triamcinolone—multiple sclerosis	0.000197	0.000541	CcSEcCtD
Cilostazol—Cough—Methotrexate—multiple sclerosis	0.000196	0.00054	CcSEcCtD
Cilostazol—Pruritus—Methylprednisolone—multiple sclerosis	0.000196	0.00054	CcSEcCtD
Cilostazol—Dyspepsia—Prednisone—multiple sclerosis	0.000194	0.000532	CcSEcCtD
Cilostazol—PDE3A—G alpha (s) signalling events—PTGER4—multiple sclerosis	0.000192	0.0123	CbGpPWpGaD
Cilostazol—Myalgia—Methotrexate—multiple sclerosis	0.000192	0.000527	CcSEcCtD
Cilostazol—Arthralgia—Methotrexate—multiple sclerosis	0.000192	0.000527	CcSEcCtD
Cilostazol—Chest pain—Methotrexate—multiple sclerosis	0.000192	0.000527	CcSEcCtD
Cilostazol—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000191	0.0122	CbGpPWpGaD
Cilostazol—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000191	0.0122	CbGpPWpGaD
Cilostazol—Decreased appetite—Prednisone—multiple sclerosis	0.000191	0.000525	CcSEcCtD
Cilostazol—Rash—Prednisolone—multiple sclerosis	0.000191	0.000524	CcSEcCtD
Cilostazol—Dermatitis—Prednisolone—multiple sclerosis	0.000191	0.000524	CcSEcCtD
Cilostazol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.00019	0.000523	CcSEcCtD
Cilostazol—Diarrhoea—Methylprednisolone—multiple sclerosis	0.00019	0.000522	CcSEcCtD
Cilostazol—Headache—Prednisolone—multiple sclerosis	0.00019	0.000521	CcSEcCtD
Cilostazol—Discomfort—Methotrexate—multiple sclerosis	0.000189	0.000521	CcSEcCtD
Cilostazol—CYP2C19—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000189	0.012	CbGpPWpGaD
Cilostazol—CYP2C19—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000189	0.012	CbGpPWpGaD
Cilostazol—Dizziness—Triamcinolone—multiple sclerosis	0.000184	0.000506	CcSEcCtD
Cilostazol—Dizziness—Methylprednisolone—multiple sclerosis	0.000184	0.000505	CcSEcCtD
Cilostazol—Infection—Methotrexate—multiple sclerosis	0.000183	0.000502	CcSEcCtD
Cilostazol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000181	0.0116	CbGpPWpGaD
Cilostazol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000181	0.0116	CbGpPWpGaD
Cilostazol—Feeling abnormal—Prednisone—multiple sclerosis	0.000181	0.000498	CcSEcCtD
Cilostazol—Asthenia—Dexamethasone—multiple sclerosis	0.000181	0.000498	CcSEcCtD
Cilostazol—Asthenia—Betamethasone—multiple sclerosis	0.000181	0.000498	CcSEcCtD
Cilostazol—Nervous system disorder—Methotrexate—multiple sclerosis	0.00018	0.000495	CcSEcCtD
Cilostazol—Thrombocytopenia—Methotrexate—multiple sclerosis	0.00018	0.000495	CcSEcCtD
Cilostazol—Gastrointestinal pain—Prednisone—multiple sclerosis	0.00018	0.000494	CcSEcCtD
Cilostazol—Nausea—Prednisolone—multiple sclerosis	0.00018	0.000494	CcSEcCtD
Cilostazol—Pruritus—Betamethasone—multiple sclerosis	0.000179	0.000491	CcSEcCtD
Cilostazol—Pruritus—Dexamethasone—multiple sclerosis	0.000179	0.000491	CcSEcCtD
Cilostazol—Skin disorder—Methotrexate—multiple sclerosis	0.000179	0.000491	CcSEcCtD
Cilostazol—Vomiting—Triamcinolone—multiple sclerosis	0.000177	0.000486	CcSEcCtD
Cilostazol—Vomiting—Methylprednisolone—multiple sclerosis	0.000177	0.000485	CcSEcCtD
Cilostazol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000176	0.0112	CbGpPWpGaD
Cilostazol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000176	0.0112	CbGpPWpGaD
Cilostazol—Rash—Triamcinolone—multiple sclerosis	0.000175	0.000482	CcSEcCtD
Cilostazol—Dermatitis—Triamcinolone—multiple sclerosis	0.000175	0.000482	CcSEcCtD
Cilostazol—Anorexia—Methotrexate—multiple sclerosis	0.000175	0.000481	CcSEcCtD
Cilostazol—Rash—Methylprednisolone—multiple sclerosis	0.000175	0.000481	CcSEcCtD
Cilostazol—Dermatitis—Methylprednisolone—multiple sclerosis	0.000175	0.000481	CcSEcCtD
Cilostazol—Urticaria—Prednisone—multiple sclerosis	0.000175	0.00048	CcSEcCtD
Cilostazol—Headache—Triamcinolone—multiple sclerosis	0.000174	0.000479	CcSEcCtD
Cilostazol—Headache—Methylprednisolone—multiple sclerosis	0.000174	0.000478	CcSEcCtD
Cilostazol—Abdominal pain—Prednisone—multiple sclerosis	0.000174	0.000478	CcSEcCtD
Cilostazol—Body temperature increased—Prednisone—multiple sclerosis	0.000174	0.000478	CcSEcCtD
Cilostazol—CYP2D6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000174	0.0111	CbGpPWpGaD
Cilostazol—CYP2D6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000174	0.0111	CbGpPWpGaD
Cilostazol—PDE3A—Hemostasis—CD58—multiple sclerosis	0.000173	0.011	CbGpPWpGaD
Cilostazol—PDE3A—Hemostasis—MERTK—multiple sclerosis	0.000173	0.011	CbGpPWpGaD
Cilostazol—PDE3A—Hemostasis—SELPLG—multiple sclerosis	0.000173	0.011	CbGpPWpGaD
Cilostazol—Diarrhoea—Betamethasone—multiple sclerosis	0.000173	0.000475	CcSEcCtD
Cilostazol—Diarrhoea—Dexamethasone—multiple sclerosis	0.000173	0.000475	CcSEcCtD
Cilostazol—Hypotension—Methotrexate—multiple sclerosis	0.000172	0.000472	CcSEcCtD
Cilostazol—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000167	0.00046	CcSEcCtD
Cilostazol—Dizziness—Betamethasone—multiple sclerosis	0.000167	0.000459	CcSEcCtD
Cilostazol—Dizziness—Dexamethasone—multiple sclerosis	0.000167	0.000459	CcSEcCtD
Cilostazol—Insomnia—Methotrexate—multiple sclerosis	0.000166	0.000457	CcSEcCtD
Cilostazol—Nausea—Triamcinolone—multiple sclerosis	0.000165	0.000454	CcSEcCtD
Cilostazol—Paraesthesia—Methotrexate—multiple sclerosis	0.000165	0.000454	CcSEcCtD
Cilostazol—Nausea—Methylprednisolone—multiple sclerosis	0.000165	0.000453	CcSEcCtD
Cilostazol—Dyspnoea—Methotrexate—multiple sclerosis	0.000164	0.00045	CcSEcCtD
Cilostazol—Dyspepsia—Methotrexate—multiple sclerosis	0.000162	0.000445	CcSEcCtD
Cilostazol—Vomiting—Betamethasone—multiple sclerosis	0.000161	0.000441	CcSEcCtD
Cilostazol—Vomiting—Dexamethasone—multiple sclerosis	0.000161	0.000441	CcSEcCtD
Cilostazol—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.00016	0.0102	CbGpPWpGaD
Cilostazol—Decreased appetite—Methotrexate—multiple sclerosis	0.00016	0.000439	CcSEcCtD
Cilostazol—Rash—Betamethasone—multiple sclerosis	0.000159	0.000438	CcSEcCtD
Cilostazol—Rash—Dexamethasone—multiple sclerosis	0.000159	0.000438	CcSEcCtD
Cilostazol—Dermatitis—Dexamethasone—multiple sclerosis	0.000159	0.000437	CcSEcCtD
Cilostazol—Dermatitis—Betamethasone—multiple sclerosis	0.000159	0.000437	CcSEcCtD
Cilostazol—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000159	0.000436	CcSEcCtD
Cilostazol—Headache—Dexamethasone—multiple sclerosis	0.000158	0.000435	CcSEcCtD
Cilostazol—Headache—Betamethasone—multiple sclerosis	0.000158	0.000435	CcSEcCtD
Cilostazol—Asthenia—Prednisone—multiple sclerosis	0.000158	0.000434	CcSEcCtD
Cilostazol—Pain—Methotrexate—multiple sclerosis	0.000157	0.000432	CcSEcCtD
Cilostazol—Pruritus—Prednisone—multiple sclerosis	0.000156	0.000428	CcSEcCtD
Cilostazol—CYP2C19—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000155	0.00989	CbGpPWpGaD
Cilostazol—CYP2C19—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000155	0.00989	CbGpPWpGaD
Cilostazol—Feeling abnormal—Methotrexate—multiple sclerosis	0.000151	0.000416	CcSEcCtD
Cilostazol—Diarrhoea—Prednisone—multiple sclerosis	0.00015	0.000413	CcSEcCtD
Cilostazol—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.00015	0.000413	CcSEcCtD
Cilostazol—Nausea—Betamethasone—multiple sclerosis	0.00015	0.000412	CcSEcCtD
Cilostazol—Nausea—Dexamethasone—multiple sclerosis	0.00015	0.000412	CcSEcCtD
Cilostazol—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000149	0.00951	CbGpPWpGaD
Cilostazol—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000149	0.00951	CbGpPWpGaD
Cilostazol—CYP3A7—Biological oxidations—CYP24A1—multiple sclerosis	0.000147	0.0094	CbGpPWpGaD
Cilostazol—CYP3A7—Biological oxidations—CYP27B1—multiple sclerosis	0.000147	0.0094	CbGpPWpGaD
Cilostazol—CYP1A2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000147	0.00938	CbGpPWpGaD
Cilostazol—CYP1A2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000147	0.00938	CbGpPWpGaD
Cilostazol—Urticaria—Methotrexate—multiple sclerosis	0.000146	0.000401	CcSEcCtD
Cilostazol—CYP3A7—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000145	0.00927	CbGpPWpGaD
Cilostazol—CYP3A7—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000145	0.00927	CbGpPWpGaD
Cilostazol—Dizziness—Prednisone—multiple sclerosis	0.000145	0.0004	CcSEcCtD
Cilostazol—Abdominal pain—Methotrexate—multiple sclerosis	0.000145	0.000399	CcSEcCtD
Cilostazol—Body temperature increased—Methotrexate—multiple sclerosis	0.000145	0.000399	CcSEcCtD
Cilostazol—CYP2D6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000143	0.0091	CbGpPWpGaD
Cilostazol—CYP2D6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000143	0.0091	CbGpPWpGaD
Cilostazol—Vomiting—Prednisone—multiple sclerosis	0.00014	0.000384	CcSEcCtD
Cilostazol—Rash—Prednisone—multiple sclerosis	0.000139	0.000381	CcSEcCtD
Cilostazol—Dermatitis—Prednisone—multiple sclerosis	0.000139	0.000381	CcSEcCtD
Cilostazol—Headache—Prednisone—multiple sclerosis	0.000138	0.000379	CcSEcCtD
Cilostazol—Asthenia—Methotrexate—multiple sclerosis	0.000132	0.000362	CcSEcCtD
Cilostazol—Nausea—Prednisone—multiple sclerosis	0.000131	0.000359	CcSEcCtD
Cilostazol—Pruritus—Methotrexate—multiple sclerosis	0.00013	0.000357	CcSEcCtD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.000128	0.00815	CbGpPWpGaD
Cilostazol—Diarrhoea—Methotrexate—multiple sclerosis	0.000126	0.000346	CcSEcCtD
Cilostazol—Dizziness—Methotrexate—multiple sclerosis	0.000122	0.000334	CcSEcCtD
Cilostazol—CYP1A2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000121	0.00771	CbGpPWpGaD
Cilostazol—CYP1A2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000121	0.00771	CbGpPWpGaD
Cilostazol—Vomiting—Methotrexate—multiple sclerosis	0.000117	0.000321	CcSEcCtD
Cilostazol—Rash—Methotrexate—multiple sclerosis	0.000116	0.000318	CcSEcCtD
Cilostazol—Dermatitis—Methotrexate—multiple sclerosis	0.000116	0.000318	CcSEcCtD
Cilostazol—Headache—Methotrexate—multiple sclerosis	0.000115	0.000316	CcSEcCtD
Cilostazol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000115	0.00734	CbGpPWpGaD
Cilostazol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000115	0.00734	CbGpPWpGaD
Cilostazol—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000114	0.00724	CbGpPWpGaD
Cilostazol—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000114	0.00724	CbGpPWpGaD
Cilostazol—Nausea—Methotrexate—multiple sclerosis	0.000109	0.0003	CcSEcCtD
Cilostazol—PDE3A—Hemostasis—PLEK—multiple sclerosis	0.000107	0.00683	CbGpPWpGaD
Cilostazol—CYP3A5—Biological oxidations—CYP27B1—multiple sclerosis	0.000107	0.0068	CbGpPWpGaD
Cilostazol—CYP3A5—Biological oxidations—CYP24A1—multiple sclerosis	0.000107	0.0068	CbGpPWpGaD
Cilostazol—CYP3A5—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000105	0.0067	CbGpPWpGaD
Cilostazol—CYP3A5—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000105	0.0067	CbGpPWpGaD
Cilostazol—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000103	0.00658	CbGpPWpGaD
Cilostazol—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	9.33e-05	0.00595	CbGpPWpGaD
Cilostazol—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	9.33e-05	0.00595	CbGpPWpGaD
Cilostazol—PDE3A—G alpha (s) signalling events—POMC—multiple sclerosis	9.1e-05	0.0058	CbGpPWpGaD
Cilostazol—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	8.97e-05	0.00572	CbGpPWpGaD
Cilostazol—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	8.25e-05	0.00526	CbGpPWpGaD
Cilostazol—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	8.24e-05	0.00525	CbGpPWpGaD
Cilostazol—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	8.24e-05	0.00525	CbGpPWpGaD
Cilostazol—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	8.13e-05	0.00518	CbGpPWpGaD
Cilostazol—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	8.13e-05	0.00518	CbGpPWpGaD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	8.03e-05	0.00512	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—S1PR1—multiple sclerosis	7.8e-05	0.00497	CbGpPWpGaD
Cilostazol—CYP3A7—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.7e-05	0.00491	CbGpPWpGaD
Cilostazol—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	7.68e-05	0.0049	CbGpPWpGaD
Cilostazol—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	7.58e-05	0.00483	CbGpPWpGaD
Cilostazol—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	7.58e-05	0.00483	CbGpPWpGaD
Cilostazol—PDE3A—Hemostasis—SELE—multiple sclerosis	7.54e-05	0.00481	CbGpPWpGaD
Cilostazol—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	7.48e-05	0.00477	CbGpPWpGaD
Cilostazol—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	7.48e-05	0.00477	CbGpPWpGaD
Cilostazol—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	7.09e-05	0.00452	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—S1PR1—multiple sclerosis	7.09e-05	0.00452	CbGpPWpGaD
Cilostazol—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	6.99e-05	0.00445	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—RGS1—multiple sclerosis	6.63e-05	0.00423	CbGpPWpGaD
Cilostazol—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	6.42e-05	0.00409	CbGpPWpGaD
Cilostazol—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	6.42e-05	0.00409	CbGpPWpGaD
Cilostazol—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	6.33e-05	0.00404	CbGpPWpGaD
Cilostazol—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	6.33e-05	0.00404	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—GPR65—multiple sclerosis	6.29e-05	0.00401	CbGpPWpGaD
Cilostazol—CYP3A7—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.24e-05	0.00398	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—RGS1—multiple sclerosis	6.02e-05	0.00384	CbGpPWpGaD
Cilostazol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	5.93e-05	0.00378	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—CXCL13—multiple sclerosis	5.75e-05	0.00367	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—CCR1—multiple sclerosis	5.75e-05	0.00367	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—GPR65—multiple sclerosis	5.71e-05	0.00364	CbGpPWpGaD
Cilostazol—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.57e-05	0.00355	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—LINGO1—multiple sclerosis	5.52e-05	0.00352	CbGpPWpGaD
Cilostazol—PDE3A—Hemostasis—ITGA4—multiple sclerosis	5.45e-05	0.00348	CbGpPWpGaD
Cilostazol—PDE3A—Hemostasis—IFNB1—multiple sclerosis	5.41e-05	0.00345	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—CCR1—multiple sclerosis	5.22e-05	0.00333	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—CXCL13—multiple sclerosis	5.22e-05	0.00333	CbGpPWpGaD
Cilostazol—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	4.96e-05	0.00316	CbGpPWpGaD
Cilostazol—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	4.96e-05	0.00316	CbGpPWpGaD
Cilostazol—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	4.89e-05	0.00312	CbGpPWpGaD
Cilostazol—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	4.89e-05	0.00312	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—TAGAP—multiple sclerosis	4.79e-05	0.00305	CbGpPWpGaD
Cilostazol—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.51e-05	0.00288	CbGpPWpGaD
Cilostazol—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.31e-05	0.00275	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—S1PR1—multiple sclerosis	4.19e-05	0.00267	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—GPC5—multiple sclerosis	4.07e-05	0.0026	CbGpPWpGaD
Cilostazol—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	3.96e-05	0.00252	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—PTGER4—multiple sclerosis	3.95e-05	0.00252	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—CXCR3—multiple sclerosis	3.81e-05	0.00243	CbGpPWpGaD
Cilostazol—PDE3A—Hemostasis—IL2RA—multiple sclerosis	3.72e-05	0.00238	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—CCL3—multiple sclerosis	3.72e-05	0.00237	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—CCR2—multiple sclerosis	3.71e-05	0.00236	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—PTGER4—multiple sclerosis	3.58e-05	0.00228	CbGpPWpGaD
Cilostazol—CYP3A7—Metabolism—SRM—multiple sclerosis	3.58e-05	0.00228	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—RGS1—multiple sclerosis	3.56e-05	0.00227	CbGpPWpGaD
Cilostazol—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.49e-05	0.00223	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—CXCR3—multiple sclerosis	3.46e-05	0.00221	CbGpPWpGaD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	3.45e-05	0.0022	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—CNR1—multiple sclerosis	3.42e-05	0.00218	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—GPR65—multiple sclerosis	3.37e-05	0.00215	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—CCR2—multiple sclerosis	3.37e-05	0.00215	CbGpPWpGaD
Cilostazol—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	3.35e-05	0.00214	CbGpPWpGaD
Cilostazol—CYP3A7—Biological oxidations—POMC—multiple sclerosis	3.32e-05	0.00212	CbGpPWpGaD
Cilostazol—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.21e-05	0.00205	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	3.16e-05	0.00202	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	3.16e-05	0.00202	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—CNR1—multiple sclerosis	3.11e-05	0.00198	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—CXCL13—multiple sclerosis	3.09e-05	0.00197	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—CCR1—multiple sclerosis	3.09e-05	0.00197	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—CXCL10—multiple sclerosis	3.08e-05	0.00196	CbGpPWpGaD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	3.08e-05	0.00196	CbGpPWpGaD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	3.07e-05	0.00196	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—CXCL10—multiple sclerosis	2.8e-05	0.00178	CbGpPWpGaD
Cilostazol—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.72e-05	0.00173	CbGpPWpGaD
Cilostazol—PDE3A—Hemostasis—ALB—multiple sclerosis	2.69e-05	0.00172	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—CCL5—multiple sclerosis	2.65e-05	0.00169	CbGpPWpGaD
Cilostazol—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	2.59e-05	0.00165	CbGpPWpGaD
Cilostazol—CYP3A5—Metabolism—SRM—multiple sclerosis	2.59e-05	0.00165	CbGpPWpGaD
Cilostazol—CYP3A7—Metabolism—CYP27B1—multiple sclerosis	2.52e-05	0.00161	CbGpPWpGaD
Cilostazol—CYP3A7—Metabolism—CYP24A1—multiple sclerosis	2.52e-05	0.00161	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	2.47e-05	0.00157	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	2.47e-05	0.00157	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—CCL5—multiple sclerosis	2.41e-05	0.00154	CbGpPWpGaD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	2.4e-05	0.00153	CbGpPWpGaD
Cilostazol—CYP3A5—Biological oxidations—POMC—multiple sclerosis	2.4e-05	0.00153	CbGpPWpGaD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	2.39e-05	0.00153	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—CCR5—multiple sclerosis	2.39e-05	0.00152	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—IL2RA—multiple sclerosis	2.35e-05	0.0015	CbGpPWpGaD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	2.35e-05	0.0015	CbGpPWpGaD
Cilostazol—CYP3A7—Metabolism—GPC5—multiple sclerosis	2.31e-05	0.00147	CbGpPWpGaD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	2.23e-05	0.00142	CbGpPWpGaD
Cilostazol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	2.23e-05	0.00142	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—CCL3—multiple sclerosis	2.2e-05	0.0014	CbGpPWpGaD
Cilostazol—PDE3A—Hemostasis—IL2—multiple sclerosis	2.18e-05	0.00139	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—CCR5—multiple sclerosis	2.17e-05	0.00138	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—IL2RA—multiple sclerosis	2.14e-05	0.00136	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—PTGER4—multiple sclerosis	2.12e-05	0.00135	CbGpPWpGaD
Cilostazol—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.1e-05	0.00134	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—PGR—multiple sclerosis	2.08e-05	0.00133	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—CXCR3—multiple sclerosis	2.04e-05	0.0013	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—CD28—multiple sclerosis	2.02e-05	0.00129	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism—SRM—multiple sclerosis	2e-05	0.00128	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—CCR2—multiple sclerosis	1.99e-05	0.00127	CbGpPWpGaD
Cilostazol—CYP3A7—Metabolism—RRM1—multiple sclerosis	1.91e-05	0.00122	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—POMC—multiple sclerosis	1.87e-05	0.00119	CbGpPWpGaD
Cilostazol—CYP2C19—Biological oxidations—POMC—multiple sclerosis	1.85e-05	0.00118	CbGpPWpGaD
Cilostazol—CYP2D6—Metabolism—SRM—multiple sclerosis	1.84e-05	0.00117	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—CNR1—multiple sclerosis	1.83e-05	0.00117	CbGpPWpGaD
Cilostazol—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	1.82e-05	0.00116	CbGpPWpGaD
Cilostazol—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	1.82e-05	0.00116	CbGpPWpGaD
Cilostazol—CYP2D6—Biological oxidations—POMC—multiple sclerosis	1.71e-05	0.00109	CbGpPWpGaD
Cilostazol—PDE3A—Hemostasis—TGFB1—multiple sclerosis	1.7e-05	0.00109	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—POMC—multiple sclerosis	1.7e-05	0.00108	CbGpPWpGaD
Cilostazol—PDE3A—Hemostasis—MAPK1—multiple sclerosis	1.67e-05	0.00107	CbGpPWpGaD
Cilostazol—CYP3A5—Metabolism—GPC5—multiple sclerosis	1.67e-05	0.00106	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—CCL2—multiple sclerosis	1.66e-05	0.00106	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—CXCL10—multiple sclerosis	1.65e-05	0.00105	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism—SRM—multiple sclerosis	1.56e-05	0.000994	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—TYK2—multiple sclerosis	1.51e-05	0.00096	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—CD86—multiple sclerosis	1.44e-05	0.000921	CbGpPWpGaD
Cilostazol—CYP1A2—Biological oxidations—POMC—multiple sclerosis	1.44e-05	0.000921	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—CCL5—multiple sclerosis	1.42e-05	0.000907	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	1.41e-05	0.000899	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	1.41e-05	0.000899	CbGpPWpGaD
Cilostazol—CYP3A5—Metabolism—RRM1—multiple sclerosis	1.38e-05	0.000881	CbGpPWpGaD
Cilostazol—PDE3A—GPCR downstream signaling—IL2—multiple sclerosis	1.38e-05	0.00088	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.38e-05	0.000878	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—SPP1—multiple sclerosis	1.32e-05	0.00084	CbGpPWpGaD
Cilostazol—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	1.3e-05	0.000827	CbGpPWpGaD
Cilostazol—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	1.3e-05	0.000827	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism—GPC5—multiple sclerosis	1.29e-05	0.000822	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—CCR5—multiple sclerosis	1.28e-05	0.000817	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—IL2RA—multiple sclerosis	1.26e-05	0.000805	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—IL2—multiple sclerosis	1.25e-05	0.000799	CbGpPWpGaD
Cilostazol—CYP3A4—Metabolism—SRM—multiple sclerosis	1.2e-05	0.000767	CbGpPWpGaD
Cilostazol—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.19e-05	0.000756	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—APOE—multiple sclerosis	1.17e-05	0.000743	CbGpPWpGaD
Cilostazol—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.11e-05	0.000711	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	1.1e-05	0.0007	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	1.1e-05	0.0007	CbGpPWpGaD
Cilostazol—CYP3A7—Metabolism—BCHE—multiple sclerosis	1.1e-05	0.0007	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.07e-05	0.000684	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism—RRM1—multiple sclerosis	1.07e-05	0.000681	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—CD80—multiple sclerosis	1.05e-05	0.000672	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism—GPC5—multiple sclerosis	1e-05	0.00064	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—POMC—multiple sclerosis	1e-05	0.000639	CbGpPWpGaD
Cilostazol—CYP2D6—Metabolism—RRM1—multiple sclerosis	9.82e-06	0.000626	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—CCL2—multiple sclerosis	9.8e-06	0.000625	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—MAPK1—multiple sclerosis	9.59e-06	0.000611	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—TYK2—multiple sclerosis	8.9e-06	0.000567	CbGpPWpGaD
Cilostazol—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	8.48e-06	0.00054	CbGpPWpGaD
Cilostazol—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	8.48e-06	0.00054	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism—RRM1—multiple sclerosis	8.32e-06	0.000531	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	8.29e-06	0.000528	CbGpPWpGaD
Cilostazol—CYP3A5—Metabolism—BCHE—multiple sclerosis	7.93e-06	0.000506	CbGpPWpGaD
Cilostazol—CYP3A4—Metabolism—GPC5—multiple sclerosis	7.75e-06	0.000494	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—IL2—multiple sclerosis	7.4e-06	0.000472	CbGpPWpGaD
Cilostazol—PDE3A—Signaling by GPCR—IL6—multiple sclerosis	7.37e-06	0.00047	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.12e-06	0.000454	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—MMP9—multiple sclerosis	7.01e-06	0.000447	CbGpPWpGaD
Cilostazol—CYP3A7—Metabolism—APOE—multiple sclerosis	6.6e-06	0.000421	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.49e-06	0.000414	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.46e-06	0.000412	CbGpPWpGaD
Cilostazol—CYP3A4—Metabolism—RRM1—multiple sclerosis	6.42e-06	0.00041	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—STAT3—multiple sclerosis	6.23e-06	0.000397	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism—BCHE—multiple sclerosis	6.13e-06	0.000391	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—MYC—multiple sclerosis	5.79e-06	0.000369	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—TGFB1—multiple sclerosis	5.77e-06	0.000368	CbGpPWpGaD
Cilostazol—CYP3A7—Metabolism—POMC—multiple sclerosis	5.67e-06	0.000362	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—MAPK1—multiple sclerosis	5.66e-06	0.000361	CbGpPWpGaD
Cilostazol—CYP2D6—Metabolism—BCHE—multiple sclerosis	5.64e-06	0.00036	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.55e-06	0.000354	CbGpPWpGaD
Cilostazol—CYP3A7—Metabolism—ALB—multiple sclerosis	5.17e-06	0.00033	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.06e-06	0.000322	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism—BCHE—multiple sclerosis	4.78e-06	0.000305	CbGpPWpGaD
Cilostazol—CYP3A5—Metabolism—APOE—multiple sclerosis	4.77e-06	0.000304	CbGpPWpGaD
Cilostazol—PDE3A—Signaling Pathways—IL6—multiple sclerosis	4.35e-06	0.000277	CbGpPWpGaD
Cilostazol—CYP3A5—Metabolism—POMC—multiple sclerosis	4.1e-06	0.000261	CbGpPWpGaD
Cilostazol—CYP3A5—Metabolism—ALB—multiple sclerosis	3.74e-06	0.000238	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism—APOE—multiple sclerosis	3.69e-06	0.000235	CbGpPWpGaD
Cilostazol—CYP3A4—Metabolism—BCHE—multiple sclerosis	3.69e-06	0.000235	CbGpPWpGaD
Cilostazol—CYP2D6—Metabolism—APOE—multiple sclerosis	3.39e-06	0.000216	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism—POMC—multiple sclerosis	3.17e-06	0.000202	CbGpPWpGaD
Cilostazol—CYP2D6—Metabolism—POMC—multiple sclerosis	2.92e-06	0.000186	CbGpPWpGaD
Cilostazol—CYP2C19—Metabolism—ALB—multiple sclerosis	2.89e-06	0.000184	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism—APOE—multiple sclerosis	2.88e-06	0.000183	CbGpPWpGaD
Cilostazol—CYP2D6—Metabolism—ALB—multiple sclerosis	2.66e-06	0.00017	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism—POMC—multiple sclerosis	2.47e-06	0.000158	CbGpPWpGaD
Cilostazol—CYP1A2—Metabolism—ALB—multiple sclerosis	2.25e-06	0.000144	CbGpPWpGaD
Cilostazol—CYP3A4—Metabolism—APOE—multiple sclerosis	2.22e-06	0.000142	CbGpPWpGaD
Cilostazol—CYP3A4—Metabolism—POMC—multiple sclerosis	1.91e-06	0.000122	CbGpPWpGaD
Cilostazol—CYP3A4—Metabolism—ALB—multiple sclerosis	1.74e-06	0.000111	CbGpPWpGaD
